Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations.
“We are extremely pleased to be selected as the partner CRO for Karolinska Development after anextensive CRO selection process in 2012,” said Dr Jim Esinhart, CEO of Chiltern. “We were selected based on our compatibility with Karolinska Development’s specific development needs in terms of our global company infrastructure and our approach to deliver innovation, quality and flexibility to every project.”
Aize Smink, Chiltern’s COO, said, “A key aspect of our partnering is our early involvement in the development of studies and providing support services and consultation as needed in the product lifecycle. Together, we will work closely with the core team at Karolinska Development to achieve the goals and objectives of their pipeline.”
Karolinska’s pipeline includes 21 drugs for indications including cardiovascular, oncology and ophthalmology conditions.